442 related articles for article (PubMed ID: 38679698)
21. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
22. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding JJ; El Dika I; Abou-Alfa GK
Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
[TBL] [Abstract][Full Text] [Related]
24. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
25. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
26. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
27. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Harding JJ
Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
Jiang Y; Han QJ; Zhang J
World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
[TBL] [Abstract][Full Text] [Related]
31. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
32. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
33. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
34. Novel immunotherapy strategies for hepatobiliary cancers.
DeLeon TT; Zhou Y; Nagalo BM; Yokoda RT; Ahn DH; Ramanathan RK; Salomao MA; Aqel BA; Mahipal A; Bekaii-Saab TS; Borad MJ
Immunotherapy; 2018 Sep; 10(12):1077-1091. PubMed ID: 30185133
[TBL] [Abstract][Full Text] [Related]
35. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
36. [Strategies and challenges of immunotherapy for hepatocellular carcinoma].
Zhang HH; Chen HS
Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):457-460. PubMed ID: 32660170
[TBL] [Abstract][Full Text] [Related]
37. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
[TBL] [Abstract][Full Text] [Related]
38. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
39. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
40. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]